JP2019534241A5 - - Google Patents

Download PDF

Info

Publication number
JP2019534241A5
JP2019534241A5 JP2019511432A JP2019511432A JP2019534241A5 JP 2019534241 A5 JP2019534241 A5 JP 2019534241A5 JP 2019511432 A JP2019511432 A JP 2019511432A JP 2019511432 A JP2019511432 A JP 2019511432A JP 2019534241 A5 JP2019534241 A5 JP 2019534241A5
Authority
JP
Japan
Prior art keywords
bone
composition
amino acid
disease
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019511432A
Other languages
English (en)
Japanese (ja)
Other versions
JP6998068B2 (ja
JP2019534241A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/KR2017/009373 external-priority patent/WO2018038582A1/ko
Publication of JP2019534241A publication Critical patent/JP2019534241A/ja
Publication of JP2019534241A5 publication Critical patent/JP2019534241A5/ja
Application granted granted Critical
Publication of JP6998068B2 publication Critical patent/JP6998068B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019511432A 2016-08-26 2017-08-28 骨再生または骨形成促進用ペプチド及びその用途 Expired - Fee Related JP6998068B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2016-0109232 2016-08-26
KR20160109232 2016-08-26
PCT/KR2017/009373 WO2018038582A1 (ko) 2016-08-26 2017-08-28 골재생 또는 골형성 촉진용 펩타이드 및 그 용도

Publications (3)

Publication Number Publication Date
JP2019534241A JP2019534241A (ja) 2019-11-28
JP2019534241A5 true JP2019534241A5 (enExample) 2020-10-08
JP6998068B2 JP6998068B2 (ja) 2022-01-18

Family

ID=61245095

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019511432A Expired - Fee Related JP6998068B2 (ja) 2016-08-26 2017-08-28 骨再生または骨形成促進用ペプチド及びその用途

Country Status (6)

Country Link
US (1) US20230181677A1 (enExample)
EP (1) EP3505529A4 (enExample)
JP (1) JP6998068B2 (enExample)
KR (1) KR102012380B1 (enExample)
CN (1) CN109863163B (enExample)
WO (1) WO2018038582A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110013566B (zh) * 2019-05-24 2021-09-14 大连医科大学附属第一医院 一种复合骨修复材料的制备方法
CN117462650B (zh) * 2023-10-08 2024-09-24 南京中医药大学 一种多肽a在促进骨再生或骨修复中的用途
PL448149A1 (pl) * 2024-03-29 2025-10-06 Uniwersytet Gdański Peptyd o działaniu osteogennym oraz jego zastosowanie

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US6184205B1 (en) * 1994-07-22 2001-02-06 University Of North Carolina At Chapel Hill GRB2 SH3 binding peptides and methods of isolating and using same
JP3906924B2 (ja) 2003-02-28 2007-04-18 独立行政法人農業生物資源研究所 絹タンパクから細胞生育ペプチドの抽出と利用
KR101013999B1 (ko) * 2004-03-19 2011-02-14 재단법인서울대학교산학협력재단 표면에 골조직 형성 증진 펩타이드가 고정된 차폐막 및임플란트
US20100291593A1 (en) 2007-07-13 2010-11-18 Powell William C Method of identifying diagnostic reagents
EP2268301B1 (en) * 2008-01-24 2020-02-26 Remedor Biomed Ltd. Erythropoietin and fibronectin compositions for bone regeneration
KR100879704B1 (ko) * 2008-06-11 2009-01-22 오스템임플란트 주식회사 골유착 및 골형성을 증진시키는 올리고펩타이드
JP4722207B2 (ja) * 2009-08-06 2011-07-13 株式会社椿本チエイン ケーブル類保護案内装置
CN103509108B (zh) * 2013-08-07 2015-02-25 浙江大学 利用特征十二多肽制备家蚕丝素蛋白特异抗体的方法
CN103665142A (zh) * 2013-11-20 2014-03-26 北京博恩康生物科技有限公司 一种诱导成骨短肽及其制备方法和用途
KR101637497B1 (ko) * 2014-12-19 2016-07-07 (주)케어젠 골형성 펩타이드 및 이의 용도
KR101794401B1 (ko) * 2015-03-26 2017-11-06 윤원준 접착성 펩타이드 및 그 용도

Similar Documents

Publication Publication Date Title
ES2563646T3 (es) Composiciones y métodos relacionados con variantes de la proteína A (SpA)
JP2012518420A5 (enExample)
JP2016509011A5 (enExample)
PE20141727A1 (es) Composiciones, usos y metodos para tratamiento de trastornos y enfermedades metabolicas
JP2012511545A5 (enExample)
JP2013107899A5 (enExample)
JP2017532343A5 (enExample)
HRP20150664T1 (hr) Antikancerogeni fuzijski protein
WO2018136698A3 (en) Bone-targeting antibodies
JP2015522539A5 (enExample)
JP2018538356A5 (enExample)
ZA202302340B (en) Compositions and methods for treating celiac sprue disease
JP2019534241A5 (enExample)
EA201791238A1 (ru) Способы и композиции, в которых используются варианты полипептидов klotho
RU2017114673A (ru) Слитый белок, наночастица, состоящая из множества мономеров указанного слитого белка, и их применение
JP2006506942A5 (enExample)
RU2016152151A (ru) Препарат, содержащий фактор viii и пептиды фактора фон виллебранда
JP2019533722A5 (enExample)
ZA202201828B (en) Therapeutic fusion proteins
JP2018508530A5 (enExample)
JP2019214579A5 (enExample)
JP2014529399A5 (enExample)
AR095076A1 (es) Péptidos y composiciones para el tratamiento de daño articular
JP2016515123A5 (enExample)
MX2022004220A (es) Composición inmunogénica viva recombinante que comprende el virus de la enfermedad de newcastle (ndv) que expresa la subunidad s1 y el rbd de la proteina spike del sars-cov-2.